Abstract: The invention provides the addition of highly inhibited starch filler to gelatin-free films and soft capsules. The addition of the highly inhibited starch filler raises the solid levels during processing without substantially increasing the melt viscosity. The resultant films and capsules are transparent.

Abstract: A pharmaceutical dosage form comprising a mixture of a therapeutically effective amount of oxcarbazepine having median particle size ranging from about 15 ?m to about 26 ?m and one or more hydrophilic polymers, said mixture being formed by subjecting a suspension comprising said oxcarbazepine and a hydrophilic polymer in a solvent, to mixing in a homogenizer, optionally removing the solvent and converting the said mixture into a dosage form.

Abstract: An improved controlled release dosage form for once-daily administration of carvedilol is described. The controlled release dosage form comprises a therapeutically effective amount of carvedilol and/or a pharmaceutically acceptable salt thereof; one or more hydrophilic polymers; one or more pharmaceutically acceptable excipients; and a polyoxyalkylene block copolymer, a solid dispersion of carvedilol and an extrusion material or a combination of a polyoxyalkylene block copolymer, a solid dispersion of carvedilol and an extrusion material.

Abstract: The present invention relates to a nanodispersion composition comprising sirolimus and a surface modifier wherein effective average particle size of Sirolimus is more than 400 nm and process for preparation thereof.

Abstract: The present invention is a composition delivering effective amounts of Glucosamine, Devils Claw, and SAM in a single dosage unit.

Abstract: A capsule medication administration system includes: a first capsule for internal body marking; a second capsule for medication; a marking device which makes a marking within a living body; a drug retention section which retains a drug; a release device which releases the drug; a detection device which detects the marking; a decision device which decides whether or not a marking which has been detected by the detection device is a specified marking; and a release control device which operates the release devices if it has been decided by the decision device that it is the specified marking; wherein the first capsule comprises the marking device. The second capsule comprises the drug retention section and the release device.

Abstract: A system for delivering a therapeutic dose of a drug is disclosed. The system includes a delivery medium with therapeutic units attached thereto. The delivery medium is preferably a polymeric hydrogel matrix that has therapeutic units incorporated therein or metal nanoparticles with therapeutic units complexed thereto. The therapeutic units include nucleic acid moieties. The nucleic acid moieties preferably include strands of nucleic acid and drug moieties complexed with the strands of nucleic acid. Where the system includes a polymeric hydrogel matrix, an active drug is controllably released from the polymer hydrogel matrix to provide a therapeutic dose to a biological system or biological tissue. The active drug is controllably released from the hydrogel matrix by altering the environment the hydrogel matrix, or by enzymatic cleavage of the nucleic acid moieties or by a combination thereof.

Abstract: An olanzapine pharmaceutical composition such as a tablet is made using anhydrous lactose as an excipient.

Abstract: An oral drug delivery system comprising a coated tablet having one or more surfaces. The coated tablet further comprises a core and a coating surrounding the core. The core comprises an active ingredient composition comprising at least one active ingredient and a pharmaceutically acceptable excipient and a composition selected from a swellable composition and a reactive composition located in an immediate vicinity of one or more preselected surfaces. The coating comprising water insoluble polymer(s) and leachable component(s) is operable to be reliably removed fully from the one or more of the preselected surfaces of the tablet upon contact with an aqueous environment, but not removed from at least one of the surfaces.

Abstract: The present invention relates to modified release pharmaceutical compositions for oral administration and more particularly to modified release pharmaceutical compositions of a form of at least one selective serotonin re-uptake inhibitor selected from the group consisting of a selective serotonin reuptake inhibitor, racemic mixtures thereof, enantiomers thereof, pharmaceutically-acceptable salts thereof and combinations thereof.

Abstract: A sustained release alfuzosin hydrochloride formulation contains alfuzosin hydrochloride as about 1% to about 5% by weight of the formulation, hydrophilic polymers as about 35% to about 75% by weight of the formulation, hydrophobic polymers as about 10% to about 30% by weight of the formulation, disintegrating agents as 10% to 30% by weight of the formulation and a binder as about 2% to about 12% by weight of the formulation. The hydrophilic and hydrophobic polymers are used as the release-modulating agent to control the dissolution profile of the alfuzosin hydrochloride formulation so that the formulation releases alfuzosin hydrochloride slowly and continuously as the formulation passed through the gastrointestinal tract. The present invention also relates to a method for preparing the above formulation.

Abstract: The invention concerns the combination of a short-acting hypnotic agent and a compound of formula (I): Wherein X, Y, Z, A, B, D, Ar, R1 and R2 are as defined herein. The combination of this invention is useful in treating a variety of sleep disorders.

Abstract: The present disclosure relates to methods of regenerating cartilage. In an embodiment, a method includes initiating a release of precursor cells, including bone marrow cells and progenitor cells, into a cartilage defect; and applying a population of exogenous cells to the cartilage defect. The exogenous cells, selected from a group including chondrocytes, synoviocytes, fat pad cells, chondroprogenitor cells, mesenchymal stem cells, and any combination thereof, induce the precursor cells to form cartilage tissue through a release of factors by the exogenous cells. The factors stimulate the precursor cells to form cartilage cells. The cartilage cells then form cartilage tissue. The factors are selected from a group including transforming growth factors, fibroblast growth factors, platelet-derived growth factors, insulin-like growth factors, epidermal growth factors, interleukins, and any combination thereof. Other methods of regenerating cartilage are also disclosed.

Abstract: A cellular composition comprising a mesenchymal stem cell product and a biogel with methods for preparing and for using the composition. Tissue constructs made with the composition are also disclosed.

Abstract: Compositions comprising biopolymers such as alginates and cell attachment peptides are disclosed. Compositions may optionally further comprise cells. Methods for repairing or treating a tissues and organs with such compositions and systems for providing such compositions to tissues and organs, and methods for delivering desired proteins to individual with such compositions and systems for providing such compositions are also disclosed. In vitro methods of culturing cells are also disclosed.

Abstract: The present invention provides a topical composition for use in treating medical conditions such as fungal epithelial infections, carpal tunnel syndrome, tendonitis, and arthritis. The topical composition includes a mineral component including a source of calcium and a source of potassium, a vitamin component including a source of ascorbic acid, and an anti-inflammatory component including a source of lysine and a source of glutathione. The topical composition also includes an anti-oxidant component including a source of curcumin and an isoflavone component including a source of ipriflavone. The present invention also provides a method of forming the topical composition. The method includes combining the mineral component, the vitamin component, the anti-inflammatory component, the anti-oxidant component, and the isoflavone component.

Abstract: The role of nanoparticle composition as biodegradable carriers for variously therapeutical drugs is disclosed. Nanoparticles are synthesized by anion emulsion polymerization of two alkyl-cyanoacrylate monomers with adjusted content ratio. By modulating the compositions, particle size, hydrophobicity and degradation rate of the copolymers is controlled. Hence, to encapsulate wide range of therapeutical drugs, poly(alkyl cyanoacrylate) nanoparticles with feasible compositions are applied individually. The copolymer nanoparticles produced by n-butyl cyanoactylate (BCA) and 2-octyl cyanoacrylate (OCA), for example, were used therein. The nanoparticles composed of poly[(n-butyl cyanoacrylate)-co-(2-octyl cyanoacrylate)] and poly(2-octyl cyanoacrylate) might be adequate for therapeutical administration.

Abstract: The present invention provides a method for preparing an orally administrable formulation comprising a biologically active ingredient for controlled release in a neutral or basic environment, which comprises the steps of: (a) dispersing powder ethylcellulose with an average diameter from about 0.1 ?m to about 300 ?m in an aqueous solution to provide an aqueous dispersion, wherein the aqueous dispersion is substantially free of detergent; (b) mixing the biologically active ingredient and the aqueous dispersion obtained in step (a) to provide a mixture; and (c) spray-drying the mixture obtained in step (b) for about 10 seconds to about 2 minutes in a drying chamber at a chamber temperature of about 45° C. to about 100° C. to obtain the orally administrable formulation. An orally administrative formulation prepared by the method of the invention is also provided.

Abstract: Microcapsules possessing Lewis acid-Lewis base salt walls incorporate water-immiscible materials, such as N,N-diethyl-m-toluamide (DEET), as a core component. Such microcapsules, or similar microcapsules incorporating other core components, may be made by emulsifying a water-immiscible core component in an aqueous solution of one wall-forming reactant, such as the Lewis base, and then mixing that solution with the other wall-forming reactant, such as the Lewis acid. Various adjuvants may be included with the core component to contribute additional characteristics, such as enhancement of a controlled release characteristic or improved mechanical stability.

Abstract: The present application relates to a pharmaceutical granulate comprising Fesoterodine or a pharmaceutically acceptable salt or solvate thereof and a pharmaceutically acceptable stabilizer, which can be selected from the group consisting of sorbitol, xylitol, polydextrose, isomalt, dextrose, and combinations thereof, and is preferably a sugar alcohol selected from the group consisting of xylitol and sorbitol. The granulate is suitable for incorporation into pharmaceutical compositions comprising a gel matrix formed by at least one type of hydroxypropyl methylcellulose into which the Fesoterodine is embedded and, optionally, further excipients. In certain embodiments, the granulate is formed by a process of wet granulation.

Abstract: The present invention relates to pharmaceutical compositions comprising an analgesic agent and providing controlled release of the agent for improved treatment and prevention of pain and pain-related conditions, such as pain-related sleep disturbance. The present invention is particularly concerned with self-administered compositions.

Abstract: The invention relates generally to a system and method for treating conditions responsive to nicotine therapy. More specifically, the invention relates to pulmonary administration of a nicotine containing formulation to effect smoking cessation.

Abstract: The present invention is directed to fibrate compositions having improved pharmacokinetic profiles and reduced fed/fasted variability. The fibrate particles of the composition have an effective average particle size of less than about 2000 nm.

Abstract: The invention relates to a method for the preparation of a stable lactate metal salt in powder form, the product of said preparation, functional pre-mixes for foodstuff comprising said stable, lactate metal salt powder, and foodstuffs comprising said stable lactate metal salt powder. In the method according to the invention, a concentrate that contains lactate metal salt is processed, with cooling, in a mixer/extruder to form a powder of the lactate metal salt and subsequently the powder of the lactate metal salt is partially encapsulated by means of an encapsulating agent. According to the invention the alkali metal lactates in powder form are storage stable for at least one year.

Abstract: A combination agent containing an LHRH receptor agonist or antagonist and an androgen receptor agonist, which is useful as an agent for the prophylaxis or treatment of hormone-dependent diseases and the like, is provided.

Abstract: In a production process of granules containing a biologically active substance, variation in the elution profile of the biologically active substance is reduced by heating the temperature of granules to about 50° C. or higher and maintaining the temperature for about 1 minute or longer. By setting the spray speed to about 90 mg/min or more per 1 g of cores when a spray agent for a primary agent containing the biologically active substance is sprayed while spraying a binding liquid to the cores and setting the total feeding weight per unit area for a centrifugal fluidized bed coating granulation machine to about 1.5 g/cm2 or more, the variation in the elution profile of the biologically active substance from the granules is reduced.

Abstract: A highly porous, fast-disintegrating binder suitable for pharmaceutical applications and methods of making the same are disclosed, the binder comprising microporous particles of an aqueous-soluble cellulosic polymer and a wicking agent. Pharmaceutical compositions and fast-disintegrating dosage forms containing the binder are also disclosed.

Abstract: The present invention relates to coated particles and pharmaceutical dosage forms comprising the active substances sensitive to environmental influences. The coating of the present invention provides stability and protection of the active substance to environmental influences and in particular from oxidation and/or environmental humidity by coating.

Abstract: The present invention generally relates to controlled drug delivery. More specifically, the present invention relates to novel device/system and extracorporeally-controlled method of drug delivery. In some embodiments, the present invention provides a system comprising a thermally-active metal nanoshell; and a temperature-responsive interpenetrating polymer network having at least one therapeutic agent disposed therein; wherein the thermally-active metal nanoshell is proximate to the temperature-responsive interpenetrating polymer network. In some embodiments, the present invention relates to a particle composition comprising a thermally-active metal nanoshell and a temperature-responsive interpenetrating polymer network. A method is also provided comprising: providing a plurality of the particles; and irradiating the particles so as to effect a temperature-induced swelling of the temperature-responsive interpenetrating polymer network.

Abstract: A microparticle composition comprising a biodegradable polymer, an immunogenic single-stranded ribonucleic acid (ss-RNA) material, a biologically active macromolecule and a stabilising agent wherein the outer surface of the resulting microparticle is free from adsorbed molecules is described. The composition is effective in providing an immune response in dendritic cells, in particular by stimulating increased production of IFN-?. Methods of production and uses, in medicine, of pharmaceutical compositions derived from the microparticles are also claimed and described.

Abstract: This invention provides a method for prophylaxis or treatment of an acute inflammatory disorder, comprising administering to a patient an aliquot of the patient's blood extracted from the patient and treated ex vivo with at least two stressors selected from the group consisting of an oxidizing agent, an electromagnetic emission and elevated temperature.

Abstract: The present invention is directed to medical devices including blood storage and handling products that comprise a specific polyphosphazene and the capability of releasing nitric oxide or other smooth muscle relaxant compounds in vivo or into stored or transient flowing blood to achieve vascular dilatation, reduced adverse reactions, reduced thrombosis, reduced incidence of post-transfusion acute myocardial infarctions, and/or to improve blood storage capabilities.

Abstract: Devices, systems, and methods reduce levels of pro-inflammatory or anti-inflammatory stimulators or mediators in blood by selective adsorption. The devices, systems, and methods are useful in situations where abnormal levels of or unregulated or excessive interaction among pro-inflammatory or anti-inflammatory stimulators or mediators occur, or during events that do induce or have the potential for inducing abnormal production of pro-inflammatory or anti-inflammatory stimulators or mediators. The devices, systems, and methods serve to prevent, control, reduce, or alleviate the severity of the inflammatory response and disease states that are associated with abnormal levels of or unregulated or excessive interaction among pro-inflammatory or anti-inflammatory stimulators or mediators.

Abstract: The invention relates to a nutritional composition comprising colostrum and a fat blend that is particularly suited the treatment of intestinal dysfunction in HIV patients.

Abstract: Use of a composition comprising cartilage or chondroitin sulphate and absorbable zinc for the preparation of a food supplement or a drug suitable for promoting iron absorption in patients suffering from lack of iron.

Abstract: Due to the toxicity of antitumor agents, use of antitumor agents is limited, and thus, it is desirable to develop auxiliary agents or antitumor agents that have the effect of reducing toxicity while maintaining the antitumor effect of antitumor agents. The present invention provides antitumor agents mixed with particulate hydroxyapatite as an auxiliary agent.

Abstract: Antimicrobial compositions having a rapid and persistent antiviral and antibacterial effectiveness are disclosed. The antimicrobial compositions contain (a) a divalent zinc salt, (b) an optional disinfecting alcohol, (c) an optional antimicrobial agent, and (d) an optional organic acid, wherein the composition has a pH of about 5 or less.

Abstract: The present invention relates to production of cosmetic composition enriched with 1H216O in comparison with typical cosmetic composition. This is provided by addition to cosmetic composition a highly pure light water comprising 1H216O from about 99.76% to about 99.999% by weight of water, while the content of 1H216O in typical water is no more than 99.575% by weight of water. According to the present invention cosmetic composition enriched with 1H216O in an amount no less than 99.76% by weight of water, includes cosmetic remedy, hygienic remedy, perfumed remedy, cosmetic makeup, water for washing, water for bath.

Abstract: The present invention relates to novel methods of treating or reducing the likelihood of developing gadolinium toxicity by administering to a patient a metal chelator before, concurrently with, or after exposure to gadolinium. The novel methods comprise, inter alia, the use of iron chelators to aid patients at increased risk of developing a gadolinium-induced condition, such as nephrogenic systemic fibrosis, acute kidney injury, cardiovascular disease and accelerated senescence.

Abstract: The present invention relates to a composition comprising an effective amount of zinc-containing layered material, an effective amount of a surfactant including a surfactant with an anionic functional group, wherein the zinc-containing layered material has a relative zinc lability of greater than about 15%.

Abstract: Disclosed are compositions comprising an effective amount of a zinc containing material having an aqueous solubility within the composition of less than about 25% by weight at 25° C.; from about 5% to about 50% of a surfactant; and from about 40% to about 95% water; wherein the pH of the composition is greater than about 7. Further disclosed are compositions comprising an effective amount of a zinc containing material having an aqueous solubility within the composition of less than about 25% by weight at 25° C.; from about 5% to about 50% of a surfactant; and from about 0.1% to about 5% of a zinc ionophoric material; from about 40% to about 95% water; and wherein the pH of the composition is greater than about 7.

Abstract: The protective effect on peritoneum of L-carnitine and its lower alkanoyl derivatives, both in the form of inner or pharmaceutically acceptable salts is disclosed. Concentrations of carnitine from about 0.02 to 0.5% w/v are suitable for preparing a solution for peritoneal dialysis having higher biocompatibility and protecting peritoneum from toxic effects of continuous use of solutions for peritoneal dialysis, in particular ones containing glucose as osmotic agent. A particularly preferred embodiment is a solution for peritoneal dialysis containing carnitine, glucose and xylitol.

Abstract: This invention relates to the treatment and prevention of asthma or other forms of broncho-constriction or reversible pulmonary vasoconstriction in a mammal.

Abstract: A pharmaceutical mixture for the treatment of hepatitis and its preparation method are disclosed. The method includes the following steps: pulverize the plants, macerate and extract the plant with water, concentrate the aqueous extract as the first concentrate; add ethanol to form a precipitate, collect and concentrate the liquid phase to form the second concentrate, and dry it; pass the second concentrate through the resin, elute with water, water-ethanol mixture and ethanol, collect and concentrate the water-ethanol and ethanol elution fraction as the third concentrate, and dry it. The plants in the present invention are Boehmeria frutescens Thunberg, Boehmeria nivea or the nettle family.

Abstract: The invention relates to a herbal composition comprising extracts from Thuja, Poke, Sweet violet, Red clover, Greater celandine and Calendula; formulations containing the herbal composition; and use of the herbal composition for preventing and/or treating skin conditions and/or abnormalities.

Abstract: A composition, which includes Guarana extract 36%, Hoodia 20:1, Cha de bugre 4:1, Ginseng, Citrus Auratium, Magnolia bark extract, and black pepper, for suppressing appetite as well as a method for the weight reduction of a body by administering a dosage of the composition, are disclosed. The composition, which is preferably a 575 mg dosage, contains an amount of Guarana extract 36% within the range of from about 40% to about 70% by weight. The composition contains an amount of Hoodia 20:1 within the range of from about 12% to about 30% by weight. The composition contains an amount of Cha de bugre 4:1 within the range of from about 5% to about 25% by weight. The composition contains an amount of Ginseng within the range of from about 2.0% to about 8.0% by weight. The composition contains an amount of Citrus Auratium within the range of from about 2.0% to about 8.0% by weight. The composition contains an amount of Magnolia bark extract within the range of from about 2.0% to about 8.0% by weight.

Abstract: A nutritional composition and method is provided for increasing blood flow to skeletal muscle in an individual by supporting the biological activity of nitric oxide comprising therapeutically effective amounts of L-arginine, Crataegus extract and Artichoke flavonoids.

Abstract: A nutritional composition and method is provided for promoting weight loss or weight maintenance in an individual by supporting and enhancing thermogenesis and lipid oxidation comprising therapeutically effective amounts of yohimbine or derivatives thereof, an effective amount of Evodia rutaecarpia extract and a source of an effective amount of L-carnitine or derivatives thereof.

Abstract: Disclosed is a process for the recovery of a phytolipid composition from a vegetable oil by-product. The phytolipid composition produced comprises squalene, phytosterols, mixed tocopherols and tocotrieneols, and vegetable wax and is useful as an emollient. The phytochemical composition may be applied directly to the skin to provide emolliency. Alternatively, the phytolipid composition may be formulated in various aqueous or anhydrous cosmetic compositions such as creams, lotions, gels, ointments, lip balms, sticks, or pencils for treatment of the skin and lips. The phytolipid composition also may be incorporated into foods, beverages, and nutraceuticals to provide health benefits.

Abstract: Dermatological compositions containing a humectant, e.g., at least one of urea, ammonium lactate, and glycerin, and an emollient, e.g., at least one of Shea or cocoa butter, glycine soja sterol and hybrid sunflower oil. The compositions of the invention may be utilized for treatment or amelioration of skin disorders or adverse physiological conditions, and such compositions may be employed as a base for cosmetic or pharmaceutical formulations for dermal administration.